MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
about
Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastomaPhenotype vs genotype in the evolution of astrocytic brain tumors.Amplification and overexpression of mdm2 gene in ependymomas.The pathobiology of glioma tumorsBrain tumors in the older person.Postoperative radiotherapy of astrocytomas.MicroRNAs/TP53 feedback circuitry in glioblastoma multiformep53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study.MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cellsGenetic alterations of human brain tumors as molecular prognostic factors.Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study.Proliferation and aneusomy predict survival of young patients with astrocytoma grade II.Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.ASTROCYTOMAS AND PROGNOSIS-FROM MORPHOLOGY TO TUMOR BIOLOGY.Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas.Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival.Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.Accumulation of MDM2 in pleomorphic xanthoastrocytomas.Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.Molecular markers of prognosis in astrocytic tumors.Apoptosis and proliferation: correlation with p53 in astrocytic tumours.An update on mouse brain tumor models in cancer drug discovery.
P2860
Q24548280-204679AB-5CA6-40AE-BB6F-9C7339DD6A6CQ33834813-DFA06234-DD2E-4555-86F7-21720ABDECE8Q33902910-E3FCDFF5-BD07-4827-9977-6AE7556854F3Q33921072-63BF1EFE-8748-464A-B065-F88360B5ADEFQ34087862-EE7AC7C8-F62A-4F02-B7AB-9F94D1416832Q34210447-A5DAADB4-8D60-402B-9132-1413466B66E5Q34262423-3078EE5A-C66C-4EED-9F45-E0A859590DFCQ34583151-F2A62B8C-B6BB-4D9E-BAA0-4F89FEBFC614Q34754561-597C5547-35A3-46FD-B610-22EC5985699FQ35117832-2201DDEA-2477-46CF-93BD-5F908C7675B2Q35790323-9D8D30DC-7810-4510-8A3A-36FAA06276FAQ36321293-D86C9510-06FB-44FC-9CED-6130FC978649Q36670841-1B2E4C28-408C-4579-B98F-AD0404C6EF4EQ36695883-419F1C34-D444-4310-9991-026A2FAAC00FQ37228212-5EC11204-0B03-492E-A7A5-9A02A4ABE64DQ37749605-60C95044-D1BD-47E2-9077-1F4222CC7BC1Q40709419-6BAA4D03-D719-4524-AEF6-7D626531B7FBQ40769882-EBA97666-5923-4054-974E-9F6C11CF7662Q41157058-1AC44E30-0494-4322-9406-91D75F6311E3Q41877426-92720294-E85C-4C59-A594-8A9D9EA91602Q43081222-B07153CD-E3EB-40CB-9666-430CE568A213Q44117460-71D4235F-8AC4-4887-98A7-8AE5B64F4A55Q44705929-EEBEBF91-5ABB-47C5-8D57-2A33FE37A2F4Q47602814-60A5B72F-18F6-44AA-81E6-DC6353C31A31Q48109841-A0E2C89D-5C84-4B88-BC28-3BB4656171ABQ48164664-CABF0541-40ED-481B-976F-6D81F6F102EAQ48514271-7B3EF916-A128-4152-AFAD-AB3894A5609AQ48831857-69CC8151-F9EF-40E5-9B96-40CE9536AB56Q55467648-F6D7AED5-C46B-4C95-A1FE-E753271DE353
P2860
MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@ast
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@en
type
label
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@ast
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@en
prefLabel
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@ast
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@en
P2093
P2860
P356
P1476
MDM2 and p53 expression in gli ...... dermal growth factor receptor.
@en
P2093
E Thomas-Tsagli
G Stamoulis
K Kouzelis
M Hadjiyannakis
P Christodoulou
P Korkolopoulou
P2860
P2888
P304
P356
10.1038/BJC.1997.216
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1006989090